IBIO iBio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%
Returns
ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q3*2026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.07M | $0 | $0 | $0 | $100,000 | $200,000 | $0 | $200,000 |
| R&D expense | $6.65M | $8.56M | $3.25M | $4.28M | $3.55M | $3.22M | $1.91M | $1.88M |
| SG&A expense | $2.76M | -$2.18M | $5.11M | $5.17M | $2.50M | $2.17M | $2.97M | $2.74M |
| Operating income | -$8.34M | -$11.38M | -$8.37M | -$9.45M | -$5.95M | -$5.20M | -$4.88M | -$4.42M |
| Interest expense | — | -$46,000 | $22,000 | $41,000 | $34,000 | $44,000 | $54,000 | $57,000 |
| Pretax income | -$7.55M | — | — | — | -$5.72M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.55M | -$10.60M | -$7.73M | -$8.99M | -$5.72M | -$5.16M | -$4.86M | -$4.36M |
| EBITDA | -$8.19M | -$11.23M | -$8.22M | -$9.30M | -$5.83M | -$5.08M | -$4.76M | -$4.30M |
| EPS (basic) | -0.05 | — | -0.06 | -0.09 | -0.11 | — | -0.49 | -0.48 |
| EPS (diluted) | -0.05 | — | -0.06 | -0.09 | -0.11 | — | -0.49 | -0.48 |
| Weighted avg. shares (diluted) | 151.57M | — | 119.60M | 99.13M | 52.98M | — | 9.86M | 9.13M |
| Balance sheet | ||||||||
| Cash & equivalents | $45.44M | $56.40M | $47.63M | $28.67M | $28.34M | $8.79M | $5.18M | $7.24M |
| Short-term investments | $31.22M | $31.64M | $27.19M | $24.02M | $21.47M | $0 | — | — |
| Receivables | $125,000 | — | — | — | $65,000 | $0 | — | — |
| Current assets | $81.24M | $92.22M | $77.25M | $53.37M | $50.77M | $9.72M | $6.06M | $8.29M |
| PP&E, net | $3.02M | $3.09M | $3.31M | $3.45M | $3.21M | $3.16M | $3.28M | $3.39M |
| Intangibles | $2.57M | $1.82M | $1.83M | $4.34M | $6.84M | $6.85M | $6.10M | $6.11M |
| Total assets | $88.65M | $99.11M | $85.83M | $64.39M | $64.16M | $23.18M | $19.10M | $21.70M |
| Current liabilities | $8.57M | $11.74M | $6.50M | $5.90M | $6.05M | $6.11M | $5.40M | $4.71M |
| Total liabilities | $10.08M | $13.40M | $8.30M | $7.83M | $8.12M | $8.30M | $7.72M | $7.80M |
| Shareholders' equity | $78.57M | $85.71M | $77.54M | $56.56M | $56.04M | $14.88M | $11.38M | $13.89M |
| Shares outstanding | 64.31M | 55.70M | 34.54M | 30.05M | 20.25M | 19.35M | 10.07M | 9.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.39M | -$6.23M | -$6.08M | -$5.24M | -$5.67M | -$4.62M | -$3.10M | -$3.87M |
| Capital expenditure | $102,000 | $19,000 | $11,000 | $516,000 | $32,000 | $1,000 | $14,000 | $1,000 |
| Free cash flow | -$9.49M | -$6.25M | -$6.09M | -$5.76M | -$5.70M | -$4.62M | -$3.12M | -$3.87M |
| Investing cash flow | -$454,000 | -$4.41M | -$3.11M | -$2.98M | -$21.49M | $45,000 | -$14,000 | -$2,000 |
| Financing cash flow | -$1.12M | $19.40M | $28.15M | $8.79M | $46.70M | $8.18M | $1.06M | -$152,000 |
| Depreciation & amortization | $145,000 | $147,000 | $147,000 | $141,000 | $123,000 | $121,000 | $121,000 | $122,000 |
| Stock-based compensation | $435,000 | $420,000 | $377,000 | $253,000 | $323,000 | $270,000 | $370,000 | $475,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.